Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study

Intensive Care Med. 2017 Apr;43(4):509-518. doi: 10.1007/s00134-017-4717-0. Epub 2017 Mar 7.

Abstract

Purpose: The aim of the study was to describe the characteristics of cirrhotic patients with candidemia and intra-abdominal candidiasis (IAC) and to evaluate the risk factors associated with 30-day mortality.

Methods: A multicenter multinational retrospective study including all consecutive episodes of candidemia and IAC in adult patients with liver cirrhosis in 14 European hospitals during the period 2011-2013 was performed.

Results: A total of 241 episodes (169 candidemia, 72 IAC) were included. Most Candida infections were acquired in hospital (208, 86.3%), mainly in the intensive care unit (ICU) (121, 50.2%). At clinical presentation, fever was seen in 60.6% of episodes (146/241) and septic shock in 34.9% (84/241). C. albicans was the most common species (found in 131 episodes, 54.4%), followed by C. glabrata (35, 14.5%) and C. parapsilosis (34, 14.1%). Overall, the 30-day mortality was 35.3%. Multivariable analysis identified candidemia (OR 2.2, 95% CI 1.2-4.5) and septic shock (OR 3.2, 95% CI 1.7-6) as independent factors associated with 30-day mortality. Adequate antifungal treatment (OR 0.4, 95% CI 0.3-0.9) was associated with survival benefit.

Conclusions: A shift towards increasing prevalence of C. glabrata and C. parapsilosis species in patients with liver disease was documented. Candidemia and IAC were associated with significant mortality in cirrhotic patients. Thirty-day mortality was associated with candidemia and severe clinical presentation, whereas adequate antifungal treatment improved the prognosis.

Keywords: Candida; Candidemia; Cirrhosis; Intra-abdominal candidiasis; Invasive candidiasis.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Antifungal Agents / therapeutic use*
  • Candida / isolation & purification
  • Candidemia / complications
  • Candidemia / drug therapy
  • Candidemia / mortality*
  • Comorbidity
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Cross Infection / mortality*
  • Echinocandins / therapeutic use
  • Europe / epidemiology
  • Female
  • Humans
  • Intensive Care Units
  • Intraabdominal Infections / drug therapy
  • Intraabdominal Infections / etiology
  • Liver Cirrhosis / complications*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Retrospective Studies
  • Risk Factors
  • Shock, Septic / drug therapy
  • Shock, Septic / microbiology
  • Shock, Septic / mortality*
  • Time Factors

Substances

  • Antifungal Agents
  • Echinocandins